Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807668001> ?p ?o ?g. }
- W2807668001 endingPage "792" @default.
- W2807668001 startingPage "786" @default.
- W2807668001 abstract "Podoplanin is a type-I transmembrane sialomucin-like glycoprotein expressed on the surface of several kinds of tumor cells. The podoplanin receptor is a platelet activation receptor known as C-type lectin-like receptor 2 (CLEC-2), which has been identified as a receptor for the platelet-activating snake venom protein rhodocytin. CLEC-2 is highly expressed in platelets and megakaryocytes and expressed at lower levels in liver Kupffer cells. Podoplanin is expressed in certain types of tumor cells, including squamous cell carcinomas, seminomas, and brain tumors. Podoplanin is also expressed in a wide range of normal cells, including fibroblastic reticular cells in lymph nodes, kidney podocytes, and lymphatic endothelial cells, but not vascular endothelial cells. Metastasis of podoplanin-positive lung tumors injected from the tail vein is greatly inhibited in CLEC-2-depleted mice or in anti-podoplanin antibody-treated mice. These findings suggest that the CLEC-2–podoplanin interaction facilitates hematogenous tumor metastasis. Platelets may increase the survival of tumor cells by covering tumor cells and physically protecting them from shear stress or immune cells in the bloodstream. Alternatively, platelets may stimulate the epithelial–mesenchymal transition of tumor cells to facilitate their extravasation from blood vessels. Cell proliferation is stimulated in podoplanin-expressing tumor cells by the coculture with platelets, but the effects of the CLEC-2–podoplanin interaction on tumor growth in vivo are not yet resolved. It is possible that the CLEC-2–podoplanin interaction facilitates tumor-related thrombosis, subsequent inflammation, inflammation-induced cachexia, and reduced survival. Considering these findings, anti-podoplanin and anti-CLEC-2 drugs are promising therapies for the prevention of tumor metastasis, progression, and tumor-related symptoms, which may result in longer survival in cancer patients. There are advantages and disadvantages of anti-podoplanin vs. anti-CLEC-2 therapy. Side effects in podoplanin-expressing normal tissues due to treatment with anti-podoplanin and temporal thrombocytopenia due to treatment with anti-CLEC2 are potential problems, although solutions to these problems have been reported." @default.
- W2807668001 created "2018-06-13" @default.
- W2807668001 creator A5069721725 @default.
- W2807668001 date "2018-06-04" @default.
- W2807668001 modified "2023-10-01" @default.
- W2807668001 title "Roles of the CLEC-2–podoplanin interaction in tumor progression" @default.
- W2807668001 cites W1589522166 @default.
- W2807668001 cites W1688255783 @default.
- W2807668001 cites W1795348252 @default.
- W2807668001 cites W1876007500 @default.
- W2807668001 cites W1894059737 @default.
- W2807668001 cites W1940673072 @default.
- W2807668001 cites W1964216939 @default.
- W2807668001 cites W1980934196 @default.
- W2807668001 cites W1989079867 @default.
- W2807668001 cites W1990313926 @default.
- W2807668001 cites W1994323367 @default.
- W2807668001 cites W2002967422 @default.
- W2807668001 cites W2004323071 @default.
- W2807668001 cites W2004796256 @default.
- W2807668001 cites W2006796442 @default.
- W2807668001 cites W2009726341 @default.
- W2807668001 cites W2013493530 @default.
- W2807668001 cites W2015176317 @default.
- W2807668001 cites W2016941384 @default.
- W2807668001 cites W2020051447 @default.
- W2807668001 cites W2024318945 @default.
- W2807668001 cites W2025532285 @default.
- W2807668001 cites W2034027385 @default.
- W2807668001 cites W2035465177 @default.
- W2807668001 cites W2038336599 @default.
- W2807668001 cites W2063818108 @default.
- W2807668001 cites W2065977830 @default.
- W2807668001 cites W2072564812 @default.
- W2807668001 cites W2075730871 @default.
- W2807668001 cites W2077296956 @default.
- W2807668001 cites W2081830302 @default.
- W2807668001 cites W2084558110 @default.
- W2807668001 cites W2086430491 @default.
- W2807668001 cites W2086784964 @default.
- W2807668001 cites W2088687546 @default.
- W2807668001 cites W2098875129 @default.
- W2807668001 cites W2100261477 @default.
- W2807668001 cites W2100387226 @default.
- W2807668001 cites W2107197642 @default.
- W2807668001 cites W2113255390 @default.
- W2807668001 cites W2116072433 @default.
- W2807668001 cites W2119563305 @default.
- W2807668001 cites W2124422993 @default.
- W2807668001 cites W2125118264 @default.
- W2807668001 cites W2133200424 @default.
- W2807668001 cites W2148583422 @default.
- W2807668001 cites W2151853926 @default.
- W2807668001 cites W2157095212 @default.
- W2807668001 cites W2162462569 @default.
- W2807668001 cites W2168766659 @default.
- W2807668001 cites W2171433554 @default.
- W2807668001 cites W2177802181 @default.
- W2807668001 cites W2189916683 @default.
- W2807668001 cites W2199651246 @default.
- W2807668001 cites W2206702622 @default.
- W2807668001 cites W2317915666 @default.
- W2807668001 cites W2430814939 @default.
- W2807668001 cites W2561056763 @default.
- W2807668001 cites W2561202332 @default.
- W2807668001 cites W2569189109 @default.
- W2807668001 cites W2578853149 @default.
- W2807668001 cites W2584273969 @default.
- W2807668001 cites W2587567294 @default.
- W2807668001 cites W2591836828 @default.
- W2807668001 cites W2598836317 @default.
- W2807668001 cites W2607011855 @default.
- W2807668001 cites W2616025468 @default.
- W2807668001 cites W2624804427 @default.
- W2807668001 cites W2734243012 @default.
- W2807668001 cites W2737148725 @default.
- W2807668001 cites W2793062143 @default.
- W2807668001 cites W2995308462 @default.
- W2807668001 cites W4206091134 @default.
- W2807668001 cites W4230687574 @default.
- W2807668001 cites W4231998168 @default.
- W2807668001 cites W4233871431 @default.
- W2807668001 cites W4234756439 @default.
- W2807668001 cites W4234973553 @default.
- W2807668001 cites W4240815611 @default.
- W2807668001 cites W4245027092 @default.
- W2807668001 cites W4246012010 @default.
- W2807668001 cites W4247713648 @default.
- W2807668001 cites W4249313024 @default.
- W2807668001 cites W4249606224 @default.
- W2807668001 doi "https://doi.org/10.1080/09537104.2018.1478401" @default.
- W2807668001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29863945" @default.
- W2807668001 hasPublicationYear "2018" @default.
- W2807668001 type Work @default.
- W2807668001 sameAs 2807668001 @default.
- W2807668001 citedByCount "24" @default.
- W2807668001 countsByYear W28076680012019 @default.
- W2807668001 countsByYear W28076680012020 @default.